

# Christos Papadimitriou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1477595/publications.pdf>

Version: 2024-02-01

18  
papers

155  
citations

1163117

8  
h-index

1199594

12  
g-index

18  
all docs

18  
docs citations

18  
times ranked

280  
citing authors

#	ARTICLE	IF	CITATIONS
1	One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. <i>Journal of Medical Genetics</i> , 2020, 57, 53-61.	3.2	27
2	Embryonal rhabdomyosarcoma of the uterine cervix. <i>Clinical and Translational Oncology</i> , 2009, 11, 399-402.	2.4	17
3	The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1419-1428.	2.2	15
4	Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer. <i>Cancer Biomarkers</i> , 2019, 25, 213-221.	1.7	12
5	From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	1.3	12
6	Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study. <i>BMC Cancer</i> , 2019, 19, 88.	2.6	9
7	Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. <i>Clinical Breast Cancer</i> , 2020, 20, 152-159.	2.4	9
8	PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk. <i>Journal of Human Genetics</i> , 2019, 64, 767-773.	2.3	8
9	Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece. <i>Journal of Human Genetics</i> , 2018, 63, 1149-1158.	2.3	7
10	MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1871-1877.	2.2	7
11	Assessing the landscape of ovarian serous borderline tumors. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 572-578.	2.5	7
12	BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. <i>International Journal of Cancer</i> , 2020, 147, 1334-1342.	5.1	7
13	CHEK2 Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects. <i>Cancers</i> , 2021, 13, 2106.	3.7	5
14	ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5608-TPS5608.	1.6	5
15	Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?. <i>Anticancer Research</i> , 2020, 40, 1669-1676.	1.1	3
16	A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patientsâ€™ Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece. <i>Cancers</i> , 2022, 14, 1879.	3.7	3
17	Assesment of cardiac effects of ado-trastuzumab emtansine through strain rate imaging in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13007-e13007.	1.6	1
18	Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). <i>Current Oncology</i> , 2021, 28, 5266-5277.	2.2	1